interesting to note that Ang-1 also induces thrombopoiesis, even in thrombopoietin-and c-Mpl-null animals, perhaps by inducing migration and attachment of megakaryocytes to the neovasculature. Clearly, the physical association between megakaryocytes and regenerating vessels facilitates efficient production and release of mature platelets into the circulation; whether the cellular interactions between endothelial cells and hematopoietic progenitors also promote megakaryocyte maturation remains less clear.
As the authors suggest, it is intriguing to consider using angiogenic agents to stimulate recovery following myelosuppressive therapy in the clinical arena. However, some measure of caution may be warranted, as Ang-1-Tie2 signaling is not limited to the BM vascular niche and likely has context-dependent effects. 2 While initially described as an "endothelial" receptor tyrosine kinase (RTK) having an essential role in angiogenesis and vascular remodeling, Tie2 is also expressed by HSCs and has recently emerged as a critical regulator of HSC maintenance in the osteoblastic BM niche. 3 Furthermore, Ang-1 is also expressed by HSCs and HPCs, and these cells have been shown to promote migration and vascular remodeling by Tie2-expressing endothelial cells. 4 These observations raise questions as to the precise role(s) of Ang-1-Tie2 signaling within the osteoblastic and vascular nichesand in the cellular migration between them. The integration of conserved signaling pathways, with RTKs providing "stop" and "go" signals for proliferation and differentiation of progenitors along specific lineage pathways, is a recurring theme in the regulation of developmental processes. 5 If, in the BM, Tie2 provides a "stop" signal for HSCs in the osteoblastic niche and a "go" signal for endothelial cells in the vascular niche, stimulation of short-term revascularization and thrombopoiesis with Ang-1 might also delay long-term hematopoietic reconstitution. Thus, it might be wise to tie up some loose ends before embarking on a clinical path. ■ All evaluable patients (aged Ͻ 18 years) had molecular evidence of APL. From January 1993 to June 2000, 124 children from 42 different centers were enrolled. Induction of complete remission (CR) was achieved in 96% of all eligible patients (n ϭ 110) and in 100% of those with a diagnostic white blood cell (WBC) count of 10 ϫ 10 9 /L (10 000/ L) or less (n ϭ 72). The overall survival at 10ϩ years was 89%, with event-free survival at 76%. It was determined that no child experienced a chemotherapy induction failure. The patients who did not attain CR were all early deaths (days 1, 9, and 16 from intracranial hemorrhage; day 34 from infection), and all had WBC counts at diagnosis above 10 ϫ 10 9 /L (10 000/L). Almost all relapses were seen in patients with diagnostic WBC counts of more than 10 ϫ 10 9 /L (10 000/L), and there were no central nervous system (CNS) relapses. Overall survival for patients with a diagnostic WBC count of 10 ϫ 10 9 /L (10 000/L) or less was 94%.
APL treatment Italian style: is this the cure? ----------------------------------------------------------------------------------------------------------------
Given the total number of patients studied and the length of the follow-up, these results are the best reported to date in pediatrics. However, these results come at a price. Two patients developed myelodysplasia (MDS; at 36 and 80 months from initial diagnosis) and subsequently underwent transplantation. One has survived at 16 months from the MDS diagnosis. The other "cost" is cardiac health. Although the authors do not report any clinically significant cardiac effects, it appears that the collection of cardiac testing results in long-term follow-up has not been completed. Certainly congestive heart failure (CHF) and cardiac deaths are reported in APL patients following much lower total anthracycline dosing (patients fully treated by this regimen would get the equivalent of 650 mg/m 2 daunorubicin). 1, 2 The results of this trial for "good-risk" patients with APL suggest that their treatment could be reduced in the future, thereby possibly reducing the risks for MDS and/or cardiac damage. Agents that are more specific for APL and/or less globally cytotoxic, including arsenic trioxide and gemtuzumab ozogomycin, are already available. [3] [4] [5] Early reports of their use in newly diagnosed patients strongly suggest that these agents should be introduced earlier in the treatment of patients with APL. ■ -------------------------------------------------------------------------------------------------------------- 
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Host ␥␦ T cells are shown to be a critical population for the activation of host antigenpresenting cells and subsequent induction of graft-versus-host disease (GVHD).
T he characteristic tissue distribution of acute GVHD has long puzzled researchers and clinicians alike. In this issue of Blood, Maeda and colleagues provide a potential explanation for acute GVHD's predilection for the skin and intestinal tract. The authors demonstrate that host ␥␦ T cells, which predominate in these organs, play an important role in the activation of host antigen-presenting cells (APCs) following total body irradiation. These fully activated host APCs in turn stimulate alloreactive donor ␣␤ T cells, unleashing the subsequent tissue injury characteristic of GVHD. 1 So how do ␥␦ T cells differ from ␣␤ T cells and what is their physiologic role in immunity? Although ␥␦ T cells represent only a small proportion (Ͻ 5%) of lymphocytes in the blood and peripheral lymph nodes, they are present in much larger numbers in epithelial tissues such as the skin and intestinal tract. They are unique in that they recognize both protein and nonprotein moieties in the absence of major histocompatibility complex (MHC) and thus are not dependent on antigen processing by APCs. The predominant antigens that ␥␦ T cells recognize and the requirement for the ␥␦ T-cell receptor (TCR) in this process remain unclear. To date, the epithelialassociated ␥␦ T cells are known to be capable of recognizing constitutively expressed "self"-antigens such as the MHC class I polypeptiderelated sequences and the T10/22 proteins, the latter of which are expressed in stressed epithelial cells in response to inflammation. It is clear that epithelial-based ␥␦ T cells can release proinflammatory cytokines and chemokines to augment mucosal immunity early in the immune response. 2 Conversely, they are also a critical immunoregulatory population late in immunity, helping to terminate the immune response through the production of anti-inflammatory cytokines such as interleukin-10 (IL-10). 3 Thus, it appears likely that, following total body irradiation, host ␥␦ T cells sense damage to stressed epithelial tissue in the skin and intestine to which they are juxtaposed and subsequently activate host APC trafficking through the tissue (see figure) . The mechanism(s) by which host ␥␦ T cells activate host APCs remains to be defined but appears to require cell-to-cell contact, at least in vitro according to Maeda and colleagues. The fully activated recipient APC then traffics to the regional lymph node to initiate the activation and expansion of alloreactive donor ␣␤ T cells, which are in turn attracted back to the intestine, perhaps by virtue of the chemokines secreted by the ␥␦ T cell. The final effector phase of tissue injury is then mediated by a 
